Fusion of PAX7 to FKHR by the Variant t(1;13)(p36;q14) Translocation in Alveolar Rhabdomyosarcoma RJ Davis, CM D'Cruz, MA Lovell, JA Biegel, FG Barr Cancer research 54 (11), 2869-2872, 1994 | 782 | 1994 |
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations CM D'Cruz, EJ Gunther, RB Boxer, JL Hartman, L Sintasath, SE Moody, ... Nature medicine 7 (2), 235-239, 2001 | 515 | 2001 |
Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas FG Barr, J Chatten, CM D'Cruz, AE Wilson, LE Nauta, LM Nycum, ... Jama 273 (7), 553-557, 1995 | 249 | 1995 |
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models HM Weir, RH Bradbury, M Lawson, AA Rabow, D Buttar, RJ Callis, ... Cancer research 76 (11), 3307-3318, 2016 | 208 | 2016 |
Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland CM D’Cruz, SE Moody, SR Master, JL Hartman, EA Keiper, MB Imielinski, ... Molecular endocrinology 16 (9), 2034-2051, 2002 | 207 | 2002 |
Functional microarray analysis of mammary organogenesis reveals a developmental role in adaptive thermogenesis SR Master, JL Hartman, CM D’cruz, SE Moody, EA Keiper, SI Ha, JD Cox, ... Molecular endocrinology 16 (6), 1185-1203, 2002 | 162 | 2002 |
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules SM Guichard, J Curwen, T Bihani, CM D'Cruz, JWT Yates, M Grondine, ... Molecular cancer therapeutics 14 (11), 2508-2518, 2015 | 133 | 2015 |
c-Myc transforms human mammary epithelial cells through repression of the Wnt inhibitors DKK1 and SFRP1 VH Cowling, CM D'Cruz, LA Chodosh, MD Cole Molecular and cellular biology, 2007 | 132 | 2007 |
Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy CM Blakely, AJ Stoddard, GK Belka, KD Dugan, KL Notarfrancesco, ... Cancer research 66 (12), 6421-6431, 2006 | 122 | 2006 |
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel U Hancox, S Cosulich, L Hanson, C Trigwell, C Lenaghan, R Ellston, ... Molecular cancer therapeutics 14 (1), 48-58, 2015 | 87 | 2015 |
Developmental stage determines the effects of MYC in the mammary epithelium CM Blakely, L Sintasath, CM D'Cruz, KT Hahn, KD Dugan, GK Belka, ... Oxford University Press for The Company of Biologists Limited 132 (5), 1147-1160, 2005 | 74 | 2005 |
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors BR Davies, N Guan, A Logie, C Crafter, L Hanson, V Jacobs, N James, ... Molecular cancer therapeutics 14 (11), 2441-2451, 2015 | 73 | 2015 |
The MET inhibitor AZD6094 (Savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient–derived xenograft models AG Schuller, ER Barry, RDO Jones, RE Henry, MM Frigault, G Beran, ... Clinical Cancer Research 21 (12), 2811-2819, 2015 | 73 | 2015 |
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers T Bihani, SA Ezell, B Ladd, SE Grosskurth, AM Mazzola, M Pietras, ... Oncotarget 6 (4), 2407, 2015 | 67 | 2015 |
Mammary gland development, reproductive history, and breast cancer risk LA Chodosh, CM D'Cruz, HP Gardner, SI Ha, ST Marquis, JV Rajan, ... Cancer research 59 (7_Supplement), 1765s-1772s, 1999 | 64 | 1999 |
Generation of stable PDX derived cell lines using conditional reprogramming A Borodovsky, TJ McQuiston, D Stetson, A Ahmed, D Whitston, J Zhang, ... Molecular cancer 16, 1-7, 2017 | 40 | 2017 |
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers JR Bradford, M Wappett, G Beran, A Logie, O Delpuech, H Brown, J Boros, ... Oncotarget 7 (15), 20773, 2016 | 40 | 2016 |
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation RE Henry, ER Barry, L Castriotta, B Ladd, A Markovets, G Beran, Y Ren, ... Oncotarget 7 (36), 57651, 2016 | 33 | 2016 |
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations B Ladd, AM Mazzola, T Bihani, Z Lai, J Bradford, M Collins, E Barry, ... Oncotarget 7 (34), 54120, 2016 | 25 | 2016 |
Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo Z Liu, M Wang, JV Alvarez, ME Bonney, C Chen, C D'Cruz, T Pan, ... Genome biology 9, 1-11, 2008 | 18 | 2008 |